ATC code L
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Pharmaceutical drug classificationTemplate:SHORTDESC:Pharmaceutical drug classification
| ATC code L: Antineoplastic and immunomodulating agents |
|---|
| Other ATC codes |
ATC code L Antineoplastic and immunomodulating agents is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL.[5]
National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
[edit | edit source]- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
|---|---|
| gastrointestinal tract / metabolism (A) | |
| blood and blood forming organs (B) | |
| cardiovascular system (C) | |
| skin (D) | |
| genitourinary system (G) | |
| endocrine system (H) | |
| infections and infestations (J, P, QI) | |
| malignant disease (L01–L02) | |
| immune disease (L03–L04) | |
| muscles, bones, and joints (M) | |
| brain and nervous system (N) |
|
| respiratory system (R) | |
| sensory organs (S) | |
| other ATC (V) | |
| CI monoclonal antibodies ("-mab") |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine kinase inhibitors ("-nib") |
| ||||||||
| Other |
| ||||||||
| Endogenous |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exogenous | |||||||||||||
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted | |||||||||||||||
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Retrieved from "http://70.231.62.181/index.php?title=ATC_code_L&oldid=1953565"